Company intelligence / Profile preview

Shanghai ForeFront Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai ForeFront Pharmaceutical is an R&D-driven biopharmaceutical company specializing in high-end generics and innovative drugs, particularly for oncology, anti-inflammation, antiviral, and orphan diseases. Their portfolio includes difficult-to-synthesize molecules, semisynthetic drugs, and advanced formulations (CR & SR, fixed dose combinations), with a focus on preclinical R&D programs aiming for global filings in China, US, and EU. No clinical outcomes have been publicly disclosed as of late 2024.

Therapeutic areas: ImmunologyInfectious DiseasesRare DiseasesCardiovascularOncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shanghai ForeFront Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai ForeFront Pharmaceutical.

Explore the full profile